PRESENTATION

Q2 2020 — Results presentation

Q2 2020PDF · 26 pages3.1 MB
1

-- 1 of 26 --

2nd Quarter 2020
Earnings Call
July 16, 2020

-- 2 of 26 --

Cautionary Note on Forward-looking Statements
3
This presentation contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future
operating and financial performance, product development, market position and business strategy. The reader is cautioned not to rely on these forward-looking
statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or
uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not
limited to: risks related to the impact of the COVID-19 global pandemic, such as the scope and duration of the outbreak, government actions and restrictive measures
implemented in response, material delays and cancellations of medical procedures, supply chain disruptions and other impacts to our business, or on our ability to
execute business continuity plans, as a result of the COVID-19 pandemic; economic factors, such as interest rate and currency exchange rate fluctuations; competition,
including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including
uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of
patent expirations; the ability of the company to successfully execute strategic plans; the impact of business combinations and divestitures; manufacturing difficulties or
delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or
government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global health care reforms; trends
toward health care cost containment; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international
economies and legal systems and sovereign risk; increased scrutiny of the health care industry by government agencies. A further list and descriptions of these risks,
uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 29, 2019, including in the
sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” in the company’s most recently filed Quarterly Report on
Form 10-Q and the company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov,
www.jnj.com or on request from Johnson & Johnson. Any forward-looking statement made in this presentation speaks only as of the date of this presentation. Johnson
& Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.
Cautionary Note on Non-GAAP Financial Measures
This presentation refers to certain non-GAAP financial measures. These non-GAAP financial measures should not be considered replacements for, and should be read
together with, the most comparable GAAP financial measures.
A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial
schedules of the earnings release and the Investor Relations section of the Company’s website at www.investor.jnj.com.

-- 3 of 26 --

Strategic Partnerships,
Collaborations & Licensing Arrangements
4
During the course of this morning’s presentation, we will discuss a number of products and compounds developed in collaboration
with strategic partners or licensed from other companies. The following is an acknowledgement of those relationships:
Immunology REMICADE and SIMPONI/ SIMPONI ARIA marketing partners are Schering-Plough (Ireland) Company, a subsidiary of Merck & Co., Inc. and Mitsubishi Tanabe Pharma Corporation, and TREMFYA
discovered using MorphoSys AG antibody technology
Neuroscience INVEGA SUSTENNA/ XEPLION/ INVEGA TRINZA/ TREVICTA includes technology licensed from Alkermes Pharma Ireland Limited, RISPERDAL CONSTA developed in collaboration with Alkermes, Inc
Infectious Diseases PREZCOBIX/ REZOLSTA fixed-dose combination, SYMTUZA and ODEFSEY developed in collaboration with Gilead Sciences, Inc., and JULUCA developed in collaboration with ViiV Healthcare UK
Cardiovascular/
Metabolism/Other
INVOKANA/ INVOKAMET/ VOKANAMET/ INVOKAMET XR fixed-dose combination licensed from Mitsubishi Tanabe Pharma Corporation, XARELTO co-developed with Bayer HealthCare AG, PROCRIT/
EPREX licensed from Amgen Inc., and X-Linked Retinitis Pigmentosa: AAV-RPGR licensed from MeiraGTx
Oncology
IMBRUVICA developed in collaboration and co-marketed in the U.S. with Pharmacyclics, LLC, an AbbVie company, ZYTIGA licensed from BTG International Ltd., VELCADE developed in collaboration with
Millennium: The Takeda Oncology Company, DARZALEX licensed from Genmab A/S, BALVERSA discovered in collaboration with Astex Pharmaceuticals, Inc., and cusatuzumab licensed and
developing in collaboration argenx BVBA and argenx SE, ERLEADA is licensed from Regents of California and Memorial Sloan Kettering, BCMA CAR-T licensed and developed in collaboration with
Legend Biotech USA Inc., Legend Biotech Ireland Limited (“Legend”), subsidiaries of GenScript Biotech Corporation, niraparib licensed from TESARO, Inc., an oncology-focused business within GSK, and
DuoBody platform licensed from Genmab relates to several bispecific antibody programs; ENHANZE platform licensed from Halozyme Therapeutics, Inc.
Pulmonary
Hypertension UPTRAVI license and supply agreement with Nippon Shinyaku (co-promotion in Japan), and OPSUMIT co-promotion agreement with Nippon Shinyaku in Japan
Global Public Health
Janssen’s Monovalent Ebola Vaccine is developed in collaboration with Bavarian Nordic A/S, and MVA-BN-Filo® is licensed-in from Bavarian Nordic A/S. The program has benefited from funding and
preclinical services from the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH, NIAID support included 2 product development contracts starting in 2008 and 8 pre-clinical services
contracts. This program is also receiving funding from the IMI2 Joint Undertaking under EBOVAC1 (grant nr. 115854), EBOVAC2 (grant nr. 115861), EBOVAC3 (grant nr. 800176), EBOMAN (grant nr.
115850) and EBODAC (grant nr. 115847). The IMI2 Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation program and the European Federation of
Pharmaceutical Industries and Associations (EFPIA). Further funding for the Ebola vaccine regimen has been provided by the BARDA, within the U.S. Department of Health and Human Services’ Office of
the Assistant Secretary for Preparedness and Response, under Contract Numbers HHSO100201700013C and HHSO100201500008C.. The initial work on Ebola was conducted which was extended from
2002 until 2011. 2002 and 2007 via a Cooperative Research and Development Agreement (CRADA is AI-0114) between Janssen/Crucell and the Vaccine Research Center (VRC)/NIAID, part of the NIH.
Janssen/Crucell have licenses to much of VRC’s Ebola IP specific for human adenovirus under the Ad26/Ad35 Ebola vaccine CRADA invention. VAC69120 (Filovirus multivalent vaccine) developed in
collaboration with Bavarian Nordic; funding: NIH Division of Microbiology and Infectious Diseases (DMID), under Contract Number HHSN272200800056C

-- 4 of 26 --

Sales Performance and Earnings Review
COVID-19 Vaccine Update
Capital Allocation and Guidance
Q&A
5
Agenda
1
2
3
4
Joseph J. Wolk
Executive Vice President,
Chief Financial Officer
Chris DelOrefice
Vice President,
Investor Relations
Alex Gorsky
Chairman and
Chief Executive Officer
Paul Stoffels, M.D.
Vice Chairman of the
Executive Committee &
Chief Scientific Officer
Joaquin Duato
Vice Chairman of the
Executive Committee

-- 5 of 26 --

Regional Sales Results Q2 2020 Q2 2019
% CHANGE
Reported Operational1
U.S. $9.5 $10.4 (8.3)% (8.3)%
Europe 4.1 4.7 (14.2) (11.5)
Western Hemisphere
(ex U.S.) 1.1 1.5 (22.1) (8.9)
Asia-Pacific, Africa 3.6 4.0 (9.3) (7.7)
International 8.8 10.2 (13.4) (9.6)
Worldwide (WW) $18.3 $20.6 (10.8)% (9.0)%
1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website
2 Note: Values may not add due to rounding
2nd Quarter 2020 Sales
Dollars in Billions
6

-- 6 of 26 --

(35.3)%; (34.5)%1
Q2 2020 Q2 2019
$1.67
$2.58
2nd Quarter 2020 Financial Highlights
Dollars in Billions, except EPS
Reported %; Operational %1
7
Sales
Adjusted Earnings2 Adjusted EPS2
(10.8)%; (9.0)%1
$18.3
$20.6
GAAP Earnings
(35.3)%
$3.6
$5.6
(36.0)%
Q2 2020 Q2 2019
GAAP EPS
(34.6)%
$1.36
$2.08
Q2 2020	Q2 2020 Q2 2019 Q2 2019	Q2 2020 Q2 2019
$4.4
$7.0
1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website
2 Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules in the Investors section of the company's website

-- 7 of 26 --

OTC
$1,149
Skin Health/Beauty
$1,007
Oral Care
$397
Baby Care
$356
Women's Health
$202
Wound Care/Other
$185
$3,296
(7.0%), (3.6%)
WW Sales $MM
■ Reported Growth ■ Operational Growth1
Consumer Health Highlights – 2nd Quarter 2020
OTC and Oral Care strength offset by COVID-19 impact
8
Key Drivers of Operational Performance1
OTC
• Increase primarily due to market and share growth driven by COVID-19
demand primarily in Pain. PEPCID growth due to competitive withdrawal as
well as ZARBEE’s NATURAL’s strength in the U.S. partially offset by
COVID-19 consumption declines in China in Pain and Cough & Cold
Skin Health/
Beauty
• Decline primarily driven by COVID-19 impacts in the U.S. and APAC.
NEUTROGENA market and consumption declines primarily across Sun
Care, Facial Care, and Makeup in the U.S.
Oral Care
• Increase primarily due to market and share growth for LISTERINE
mouthwash due to increased demand related to COVID-19 primarily in the
U.S.; promotional activity and new product launched in APAC
Baby Care
• Decline due to Baby Center divestiture, SKU rationalization and COVID-19
related impacts in APAC along with prior year relaunch activities in EMEA
partially offset by strength in AVEENO baby
Women’s
Health • Decline due to COVID-19 impacts driven by lockdowns and destocking
Wound
Care/Other
• Decline due to COVID-19 impacts in adhesive bandages in Japan and
reduced market demand in tapes and wraps in the U.S.
Adjusted Operational Sales2: WW (3.4)%, U.S. 2.0%, Int’l (7.5)%
Reported: WW (7.0)%, U.S. 1.3%, Int’l (13.4)%
Operational1: WW (3.6)%, U.S. 1.3%, Int’l (7.4)%
1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website
2 Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules in the Investors section of the company's website
Note: Values may not add due to rounding
7.9%, 10.7%
(20.1)%, (11.8)%
(4.0)%, (2.1)%
(19.7)%, (13.6)%
2.2%, 6.3%
(16.2)%, (14.3)%

-- 8 of 26 --

Key Drivers of Operational Performance1
Immunology
• Growth driven by strong uptake of STELARA in Crohn’s Disease and Ulcerative Colitis,
strength in TREMFYA in Psoriasis, and U.S. market growth, partially offset by COVID-19
• REMICADE decline due to increased discounts/rebates and biosimilar competition
Infectious
Diseases
• Driven by strong sales of SYMTUZA in the U.S. and launch uptake of JULUCA in the EU,
partially offset by increased competition for PREZISTA/PREZCOBIX/REZOLSTA and
PREZISTA OUS LOE
Neuroscience
• Paliperidone long-acting injectables growth due to strength of INVEGA
SUSTENNA/XEPLION and INVEGA TRINZA/TREVICTA from new patient starts and
persistency, partially offset by cannibalization of RISPERDAL CONSTA, and the negative
impact of COVID-19
Oncology
• DARZALEX continued strong market growth and share gains in the U.S., partially offset by
the negative impact of COVID-19 and a one-time pricing adjustment in the EU in 2019
• Strong sales of IMBRUVICA due to increased patient uptake globally, higher market share
primarily in CLL L1, partially offset by COVID-19
• Continued strong global launch uptake of ERLEADA and share gains in non-metastatic
CRPC as well as recently approved mCSPC indication
• Lower sales and share of VELCADE and ZYTIGA due to generic competition
Cardiovascular/
Metabolism/
Other
(CVM/Other)
• Decline driven by lower sales of PROCRIT/EPREX due to biosimilar competition
• Modest growth in XARELTO due to TRx growth and a one-time prior period pricing
adjustment, partially offset by increased rebates
• INVOKANA/INVOKAMET growth due to EU and LATAM uptake and a one-time prior period
pricing adjustment in the U.S., partially offset by U.S. share declines due to competitive
pressures and higher rebates
Pulmonary
Hypertension
(PH)
• Growth in OPSUMIT and UPTRAVI due to continued share gains, market growth, and
improved payer mix
• Lower sales of TRACLEER due to generic competition and cannibalization from OPSUMIT
Adjusted Operational Sales2: WW 3.9%, U.S. 5.8%, Int’l 1.5%
Immunology
$3,523
Infectious Diseases
$878
Neuroscience
$1,587
Oncology
$2,791 CVM/Other
$1,184
PH
$789
$10,752
2.1%, 3.9%
WW Sales $MM
■ Reported Growth ■ Operational Growth1
Pharmaceutical Highlights – 2nd Quarter 2020
Growth across most therapeutic areas despite COVID-19 impacts
9
Reported: WW 2.1%, U.S. 5.8%, Int’l (2.4)%
Operational1: WW 3.9%, U.S. 5.8%, Int’l 1.4%
1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website
2 Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules in the Investors section of the company's website
Note: Values may not add due to rounding
(7.1)%, (5.8)%
14.2%, 15.0%
3.5%, 5.7%
3.2%, 5.2%
1.9%, 4.7% 1.6%, 3.0%

-- 9 of 26 --

Orthopaedics
$1,451
Surgery
$1,551
Vision
$695
Interventional
Solutions
$590
$4,288
(33.9)%, (32.7)%
WW Sales $MM
■ Reported Growth ■ Operational Growth1
Medical Devices Highlights – 2nd Quarter 2020
Sales decline driven by the negative impact of COVID-19
10
Reported: WW (33.9)%, U.S. (39.6)%, Int’l (28.8)%
Operational1: WW (32.7)%, U.S. (39.6)%, Int’l (26.4)%
Key Drivers of Operational Performance1
Interventional
Solutions
• Driven by the negative impact of COVID-19 partially offset by double-digit growth in
China
Orthopaedics
• Hips: Driven by the negative impact of COVID-19; continued leadership position in the
anterior approach
• Knees: Driven by the negative impact of COVID-19
• Trauma: Driven by reductions in general activity, travel and recreation due to COVID-19
• Spine, Sports & Other: Driven by the negative impact of COVID-19 partially offset by
strong uptake of SYMPHONY in Spine
• Spine: WW: ~(36%), U.S.: ~(43%), OUS: ~(27%)
Surgery
• Advanced:
• Endocutters: ~(27%) Primarily driven by the negative impact of COVID-19 coupled
with competitive pressures in the U.S.
• Biosurgery: ~(13%) Driven by the negative impact of COVID-19 partially offset by
growth of SURGIFLO after prior year supply disruption
• Energy: ~(27%) Primarily driven by the negative impact of COVID-19 coupled with
competitive pressures in the U.S.
• General: Driven by the negative impact of COVID-19 and an unfavorable prior period
pricing adjustment in the U.S.
Vision
• Contact Lenses/Other: Negatively impacted by COVID-19 resulting in less new wearers
entering the category and lower consumption of existing wearers
• Surgical: Primarily driven by the negative impact of COVID-19 coupled with competitive
pressures in the U.S.
Adjusted Operational Sales2: WW (32.5)%, U.S. (39.5)%, Int’l (26.1)%
1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website
2 Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules in the Investors section of the company's website
Note: Values may not add due to rounding
(21.5)%, (20.5)%
(40.1)%, (39.3)%
(34.7)%, (33.9)%
(34.1)%, (32.2)%

-- 10 of 26 --

Condensed Consolidated Statement of Earnings
1 Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules in the Investors section of the company's website
11
2020 2019 %
Increase
(Decrease)	Amount % to Sales Amount % to Sales
Sales to customers $18,336 100.0 $20,562 100.0 (10.8)
Cost of products sold 6,579 35.9 6,940 33.8 (5.2)
Gross Profit 11,757 64.1 13,622 66.2 (13.7)
Selling, marketing, and administrative expenses 4,993 27.2 5,546 27.0 (10.0)
Research and development expense 2,707 14.8 2,666 13.0 1.5
In-process research and development 6 0.0 - -
Interest (income) expense, net 26 0.2 (5) 0.0
Other (income) expense, net 24 0.1 (1,683) (8.2)
Restructuring 61 0.3 57 0.2
Earnings before provision for taxes on income 3,940 21.5 7,041 34.2 (44.0)
Provision for taxes on income 314 1.7 1,434 6.9 (78.1)
Net Earnings $3,626 19.8 $5,607 27.3 (35.3)
-
Net earnings per share (Diluted) $1.36 $2.08 (34.6)
Average shares outstanding (Diluted) 2,665.5 2,691.7
Effective tax rate 8.0% 20.4%
.
Adjusted earnings before provision for taxes and net earnings1
Earnings before provision for taxes on income $5,337 29.1 $8,614 41.9 (38.0)
Net earnings $4,446 24.2 $6,950 33.8 (36.0)
Net earnings per share (Diluted) $1.67 $2.58 (35.3)
Effective tax rate 16.7% 19.3%
2nd Quarter 2020
(Unaudited; Dollar and Shares in Millions Except Per Share Figures)

-- 11 of 26 --

Adjusted Income Before Tax by Segment1
2nd Quarter 2020
12
Pharmaceutical
Medical Devices3
Consumer Health
Expenses Not Allocated to Segments
2Q 2020 2Q 2019
Pharmaceutical 44.1% 41.6%
Medical Devices 1.2% 57.5%
Consumer Health 24.0% 20.9%
Total 29.1% 41.9%
1 Non-GAAP measure; excludes amortization expense and special items; see reconciliation schedules in the Investors section of the company's website
2 Estimated as of 7/16/2020
3 2019 includes approximately $2.0 billion related to the divestiture of the Advanced Sterilization Products (ASP) business.
Note: Values may not add due to rounding
% to Sales

-- 12 of 26 --

COVID-19
Vaccine R&D and
Manufacturing
Update

-- 13 of 26 --



-- 14 of 26 --

Capital Allocation Strategy
Capital Allocation
Organic growth business needs
Free cash flow1
Priorities are clear and remain unchanged
Competitive dividends
Share repurchases
HIGHER
PRIORITY
LOWER
PRIORITY
Investment in M&A
Dollars in Billions Q2 2020
Cash and Marketable
Securities $19.1
Debt ($30.4)
Net Debt ($11.3)
Free Cash Flow2 ~$5.5
Q2 2020:
$2.7B invested in R&D
$2.7B in dividends paid
to shareholders
Note: values may have been rounded
1 Non-GAAP measure; cash flow from operations less CAPEX
2 Estimated as of July 16, 2020
15

-- 15 of 26 --

Healthcare
Industry
Macroeconomic Perspective
16
Encouraging trends for many procedures approaching pre-
COVID-19 levels
Patients
Office
Visits
Improving office visits compared to earlier stages of the
pandemic
Public educational materials and resources to increase
patient confidence and inspire people to prioritize their health
Consumers U.S. category growth trends improved from height of
lockdowns
The impact of the pandemic is very fluid and likely to continue evolving

-- 16 of 26 --

• Expectations remain unchanged
• Recent improvement in number of patient interactions
with Health Care Providers
• Continued above market growth
17
2020 Guidance
Pharmaceutical
• Expectations remain unchanged
• Impact to certain categories as a result of reduced store
traffic, government lockdowns, and social distancing
behaviors
• SKU rationalization program proceeding as planned
• Above market growth in the U.S.
Consumer Health
Informed Assumptions
• Utilized external expert assessments related to the macroeconomic impact of COVID-19
• Discussions with hospital systems, administrators, and surgeons on preparedness and treatment paradigm
• Extensive analytics on weekly hospital trends by account

-- 17 of 26 --

Medical Devices: Q2 Monthly Trends
18
Variance vs. Original Expectations to Start the Year (January Guidance)
Franchise June Q2
Contact Lenses (30%) (40%)
Surgical Vision (45%) (55%)
Biosurgery / Endocutters / Energy (20%) (30%)
Wound Closure (20%) (30%)
Hips (10%) (40%)
Knees (25%) (55%)
Spine (15%) (35%)
Trauma (10%) (20%)
Electrophysiology (10%) (30%)
Total Medical Devices (25%) (35%)
-50%
-40%
-30%
-20%
-10%
0%
January February March April May June
Variance
vs. Original Expectations
Medical Devices
2 Note: Values are rounded

-- 18 of 26 --

Countries Impacted:
China, Japan, Korea
• China represented more than 40%
of total MD impact in Q1
• Japan and Korea represented less
than 5% of total MD impact in Q1
• China declined (5%) vs. original
expectations in January, but
grew +11%1 vs. 2019
• Japan and Korea declined (25%)
vs. original expectations in
January Current estimate:
• Decline of (10%) to (25%)
April assumptions:
• Decline of (15%) to (35%)
Current estimate:
• Impact of (15%) to 0%
April assumptions:
• Impact of 0% to +10%
~20%
of MD Sales
Major Markets:
US, Italy, France, Germany,
UK, Russia, Spain
• U.S. represented ~30% of total
MD impact in Q1
• Remaining major markets
represented less than 20%
of total MD impact in Q1
• U.S. declined (40%) vs. original
expectations in January with
June declining (20%)
• Germany declined (25%) vs.
original expectations in January
with June declining (15%)
• Remaining markets declined
(45%) vs. original expectations
~60%
of MD Sales
Rest of World • ROW represented more than 5%
of total MD impact in Q1
• ROW declined (45%) vs.
original expectations
~20%
of MD Sales
Medical Devices: COVID-19 Framework
19
Full Year 2020 Operational Sales Impact inclusive of Q2 YTD Actuals: ($3.75B) to ($5.25B)
Initial Impact Significant Impact Stabilization Recovery
Overall economy, unemployment, insurance coverage and procedure capacity are key variables
that could impact rate of recovery
Total Worldwide
Medical Devices
Total Worldwide
Medical Devices
Q1 Q2 Q4	Q3
1 Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules in the Investors section of the company's website
1 Note: Values are rounded

-- 19 of 26 --

0
20
40
60
80
100
120
January February March April May June July August September October November December
20
Medical Devices: Procedural Guidance Update
April Guidance
Actuals
Original Expectations
% 2020 Original Expectations Attainment
Full Year 2020 Operational Sales Impact inclusive of Q2 YTD Actuals: ($3.75B) to ($5.25B)
July Guidance

-- 20 of 26 --

2020 Guidance
1 Non-GAAP measure; excludes acquisitions and divestitures 4 Non-GAAP measure; excludes intangible amortization expense and special items
2 Non-GAAP measure; excludes the impact of translational currency 5 Sales less: COGS, SM&A and R&D expenses
3 Euro Average Rate: July 2020 = $1.12
21
July April Comments
Adjusted Operational
Sales1,2 (0.8%) - 1.0% (3.0%) - 0.5% Improved Medical Devices outlook
Operational Sales2 $81.0 - $82.5B
(1.3%) - 0.5%
$79.2 - $82.2B
(3.5%) - 0.0% Net Impact Acq./Div: ~0.5%
Estimated Reported Sales 3 $79.9B - $81.4B
(2.6%) - (0.8%)
$77.5B - $80.5B
(5.5%) - (2.0%) FX ($1.1B) or (1.3%) impact
Adjusted Pre-Tax
Operating Margin4,5 ~100 bps decline ~100 bps decline
Net Interest Expense /
(Income) $50 - $150 million $50 - $150 million
Net Other Income4 $0.8 - $1.0 billion $0.8 - $1.0 billion
Effective Tax Rate4 16.5% - 17.5% 16.5% - 18.0% Tightening of range
Adjusted EPS
(Operational)2,4
$7.85 - $8.05
(9.6%) - (7.3%)
$7.65 - $8.05
(11.9%) - (7.3%) Midpoint of $7.95 or (8.4%)
Adjusted EPS (Reported)3,4 $7.75 - $7.95
(10.7%) - (8.4%)
$7.50 - $7.90
(13.6%) – (9.0%)
Midpoint of $7.85 or (9.6%)
FX ($0.10) or (1.2%) impact

-- 21 of 26 --

Pharmaceuticals
22
2021 Considerations
Enterprise Medical Devices
‒ Plan to continue above
market growth
‒ No anticipation of new
biosimilar or generic
competitors
‒ Assume procedures to
be largely permissible
throughout the year
leading to double-digit
operational sales growth
‒ Expect strong EPS
growth on an
operational basis
‒ OI&E projected to be
consistent with 2020
‒ 2020 additional 2 to 3
shipping days (53rd
week)
‒ Focus on delivering
solid growth in
stronghold categories
‒ Projecting expansion of
e-Commerce channel
‒ Full year SKU
rationalization program
profitability benefit
expected
Consumer Health

-- 22 of 26 --

Medical Devices
• Other:
– Biosense Webster unveils late-breaking results from PRECEPT study in patients with persistent atrial fibrillation
Pharmaceuticals
• Regulatory Approvals:
– IMBRUVICA (ibrutinib) – U.S. Food and Drug Administration (FDA) approval for the combination with rituximab for the treatment of patients with chronic lymphocytic
leukemia or small lymphocytic lymphoma who are new to therapy
– DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) – FDA approval of a new subcutaneous formulation of daratumumab for the treatment of patients with multiple
myeloma
– SIRTURO (bedaquiline) – FDA approval of a new pediatric formulation as part of combination therapy to treat children with pulmonary multidrug-resistant tuberculosis
– DARZALEX (daratumumab) – European Commission (EC) granted marketing authorization for subcutaneous formulation for all currently approved intravenous formulation
indications
– ZABDENO (Ad26.ZEBOV) and MYABEA (MVA-BN-Filo) – EC granted marketing authorization for the Janssen Ebola vaccine regimen for the prevention of Ebola Virus
Disease1
– TREMFYA (guselkumab) – FDA approval for the treatment of adult patients with active psoriatic arthritis1
• Regulatory Submissions:
– SIMPONI ARIA (golimumab) – Submission of two supplemental Biologics License Applications to the FDA for the treatment of polyarticular juvenile idiopathic arthritis and
juvenile psoriatic arthritis, in patients two years of age and older in combination with methotrexate
• Other:
– STELARA (ustekinumab) – Announced discontinuation of Phase 3 LOTUS study in Systemic Lupus Erythematosus
– The Company announced acceleration of its COVID-19 vaccine candidate; Phase 1/2a clinical trial to begin in second half of July
Notable New Announcements in 2nd Quarter 20201
23
1 These developments and all other news releases are available online in the Investors section of the company’s website at news releases

-- 23 of 26 --

24

-- 24 of 26 --

Q&A
Paul Stoffels, M.D.
Vice Chairman of the
Executive Committee &
Chief Scientific Officer
Chairman and
Chief Executive Officer
Alex Gorsky Joseph J. Wolk
Executive Vice President,
Chief Financial Officer
Joaquin Duato
Vice Chairman of the
Executive Committee

-- 25 of 26 --



-- 26 of 26 --